- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Cytokinetics Inc (CYTK)
Cytokinetics Inc stock price live, this page displays NASDAQ CYTK stock exchange data. View the CYTK premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Cytokinetics Inc real time stock price chart below.
What Is the Cytokinetics Inc Stock Price Today?
The Cytokinetics Inc stock price today is 61.43.
What Is the Stock Symbol for Cytokinetics Inc?
The stock symbol for Cytokinetics Inc is "CYTK."
What Stock Exchange Does Cytokinetics Inc Trade On?
Cytokinetics Inc is listed and trades on the NASDAQ stock exchange.
Is Cytokinetics Inc a Good Stock to Buy?
Determining whether Cytokinetics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CYTK quote. (ISIN: US23282W6057)
What Is the Cytokinetics Inc Stock Price Today?
The Cytokinetics Inc stock price today is 61.43.
What Is the Stock Symbol for Cytokinetics Inc?
The stock symbol for Cytokinetics Inc is "CYTK."
What Stock Exchange Does Cytokinetics Inc Trade On?
Cytokinetics Inc is listed and trades on the NASDAQ stock exchange.
Is Cytokinetics Inc a Good Stock to Buy?
Determining whether Cytokinetics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CYTK quote. (ISIN: US23282W6057)
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
60.45
62.54
52 wk Range
29.31
70.98
CYTK is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
60.4562.54
52 wk Range
29.3170.98
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CYTK Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
91.17
Upside
+48.41%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Stock has taken a big hit over the last week
- Cytokinetics receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Cytokinetics receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Cytokinetics Inc Company Profile
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Cytokinetics Inc SWOT Analysis
Aficamten's Promise | Cytokinetics' lead candidate aficamten shows potential to revolutionize hypertrophic cardiomyopathy treatment, with FDA review underway and key clinical trials in progress |
Market Disruption | Explore how aficamten's differentiated safety profile and efficacy could position it as a best-in-class therapy, potentially capturing significant market share in HCM treatment |
Financial Outlook | Analyst price targets range from $41 to $120, reflecting optimism despite current negative EPS, with expectations of strong sales growth and potential profitability improvements |
Strategic Vision | Delve into Cytokinetics' Vision 2030, aiming for multiple indications for aficamten and advancement of 10 new compounds, showcasing the company's ambitious growth plans |
Cytokinetics Inc Earnings Call Summary for Q3/2025
- Cytokinetics reported Q3 2025 EPS of -$2.55 (62.42% miss) and revenue of $1.93M (68.1% miss), while stock remained stable at $59.97 with a slight aftermarket increase.
- Net loss widened to $306.2M from $160.5M year-over-year, with R&D expenses increasing to $99.2M and G&A expenses rising to $69.5M compared to 2024.
- The company maintains a strong cash position of $1.25B and forecasts ending 2025 with approximately $1.2B to support clinical trials and commercial activities.
- Management is focused on the anticipated FDA approval of Aficamten by December 2025, with EU approval expected in H1 2026 and a supplemental NDA filing planned for early 2026.
- CEO Robert Blum described this as 'a pivotal moment in our company's history,' while EVP R&D Fady Malik called the Maple HCM trial results 'a watershed moment in OHCM treatment.'
Last Updated: 2025/11/06, 01:06
Read Full TranscriptCompare CYTK to Peers and Sector
Metrics to compare | CYTK | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCYTKPeersSector | |
|---|---|---|---|---|
P/E Ratio | −9.6x | −3.3x | −0.5x | |
PEG Ratio | 0.40 | 0.23 | 0.00 | |
Price/Book | −11.5x | 5.6x | 2.6x | |
Price / LTM Sales | 85.9x | 16.8x | 3.2x | |
Upside (Analyst Target) | 44.6% | 215.8% | 47.3% | |
Fair Value Upside | Unlock | 13.9% | 6.7% | Unlock |
Analyst Ratings
17 Buy
3 Hold
0 Sell
Ratings:
20 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 91.17
(+48.41% Upside)
Earnings
Latest Release
Feb 24, 2026
EPS / Forecast
-1.50 / -1.56
Revenue / Forecast
17.76M / 7.12M
FAQ
What Is the Cytokinetics Inc (CYTK) Stock Price Today?
The Cytokinetics Inc stock price today is 61,43 USD.
What Stock Exchange Does Cytokinetics Inc Trade On?
Cytokinetics Inc is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Cytokinetics Inc?
The stock symbol for Cytokinetics Inc is "CYTK."
What Is the Cytokinetics Inc Market Cap?
As of today, Cytokinetics Inc market cap is 7,56B USD.
What Is Cytokinetics Inc's Earnings Per Share (TTM)?
The Cytokinetics Inc EPS (TTM) is -6,54.
When Is the Next Cytokinetics Inc Earnings Date?
Cytokinetics Inc will release its next earnings report on Apr 30, 2026.
From a Technical Analysis Perspective, Is CYTK a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Cytokinetics Inc Stock Split?
Cytokinetics Inc has split 1 times.
How Many Employees Does Cytokinetics Inc Have?
Cytokinetics Inc has 498 employees.
What is the current trading status of Cytokinetics Inc (CYTK)?
As of Mar 03, 2026, Cytokinetics Inc (CYTK) is trading at a price of 61,43 USD, with a previous close of 62,22 USD. The stock has fluctuated within a day range of 60,45 USD to 62,54 USD, while its 52-week range spans from 29,31 USD to 70,98 USD.
What Is Cytokinetics Inc (CYTK) Price Target According to Analysts?
The average 12-month price target for Cytokinetics Inc is 91,17 USD, with a high estimate of 136 USD and a low estimate of 61 USD. 17 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +48,41% Upside potential.
What Is the CYTK Premarket Price?
CYTK's last pre-market stock price is 61,64 USD. The pre-market share volume is 12 940,00, and the stock has decreased by -0,58, or -0,93%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.